Recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (BRAF, NRAS)...

I'm sorry to hear your Melanoma has recurred. This can be a difficult situation, but there are treatment options available that may be helpful.

According to the NCCN Guidelines for Melanoma, when Melanoma recurs, the treatment approach depends on factors like the location of the recurrence, whether it is a local, regional, or distant recurrence, and your overall health status. The guidelines recommend considering systemic therapy options, which may include targeted therapies based on your tumor's biomarker profile.

Specifically, the NCCN Guidelines state that for patients with a BRAF mutation, BRAF/MEK targeted therapy combinations like dabrafenib plus trametinib or encorafenib plus binimetinib are recommended as first-line systemic treatment options. These targeted therapies have shown improved outcomes compared to traditional chemotherapy for patients with BRAF-mutant Melanoma.

Additionally, the American Cancer Society notes that for patients with NRAS mutations, MEK inhibitor therapies like binimetinib may be an option. Immunotherapy approaches like anti-PD-1 drugs are also recommended for many patients with recurrent Melanoma, regardless of biomarker status.

The key is to work closely with your oncology team to determine the best personalized treatment plan based on the specifics of your case and tumor characteristics. They can help you understand all the options and make an informed decision. I would encourage you to have an open discussion with your doctors about the latest Melanoma treatment approaches and how they may apply to your situation.

Please let me know if you have any other questions! I'm here to provide information, but your healthcare providers should guide the medical decision-making.

Sources:

• NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous (Version 3.2022)
• American Cancer Society. Targeted Drug Therapy for Melanoma Skin Cancer.
• FDA approvals for BRAF and MEK inhibitor therapies in Melanoma.